AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.
Agricola
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.
American Journal of Clinical Nutrition, Vol. 86, No. 3, 775-780, September 2007
© 2007 American Society for Nutrition

ORIGINAL RESEARCH COMMUNICATION

Influence of inulin on plasma isoflavone concentrations in healthy postmenopausal women1,2,3

Cateno Piazza, Maria Giovanna Privitera, Barbara Melilli, Tiziana Incognito, Maria Rosa Marano, Gian Marco Leggio, Matilde Amico Roxas and Filippo Drago

1 From the Pharmacokinetic Unit, Unifarm Research Center, University of Catania, Catania, Italy

2 Supported by the PhD School of Neuropharmacology and the Department of Experimental and Clinical Pharmacology, University of Catania, Catania, Italy.

3 Address reprint requests to F Drago, Department of Experimental and Clinical Pharmacology, University of Catania, Viale Andrea Doria 6, Catania I-95125. E-mail: fdrago{at}tin.it.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Bacterial intestinal glucosidases exert an important role in isoflavone absorption. Insoluble dietary fibers such as inulin may stimulate the growth of these bacteria in the colon and, hence, stimulate the absorption of these substances in subjects who may need isoflavone supplementation.

Objective: The objective was to assess the influence of inulin on plasma isoflavone concentrations after intake of soybean isoflavones in healthy postmenopausal women.

Design: Twelve healthy postmenopausal women participated in a randomized, double-blind, crossover study. They consumed 40 mg of a conjugated form of soybean isoflavones (6 mg daidzein and 18 mg genistein as free form) with or without 3.66 g inulin twice daily in two 21-d experimental phases. Blood samples were collected 0, 1, 2, 3, 4, 6, 10, 12, and 24 h after intake of isoflavones with breakfast and dinner at the end of each 21-d experimental phase. Plasma concentrations of isoflavones were assessed by HPLC with an electrochemical detector.

Results: Plasma 24-h areas under the curve indicated that the intake of soybean isoflavones with inulin for 21 d was followed by higher plasma concentrations of daidzein and genistein (38% and 91%, respectively) compared with the formulation without inulin. Furthermore, the time for the maximum concentration of daidzein and genistein appeared to be lower after the 21-d intake of soybean isoflavones, with or without inulin. However, the time for the maximum concentration of daidzein and genistein after supplementation with the inulin-containing formulation on day 21 was not significantly different from that after supplementation with the formulation without inulin.

Conclusions: Inulin may increase the apparent plasma concentrations of the soybean isoflavones daidzein and genistein in postmenopausal women. The higher plasma concentrations of the 2 isoflavones suggests that the absorption of each was facilitated by the presence of inulin.

Key Words: Isoflavones • plasma inulin concentrations • postmenopausal women


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The role of dietary flavonoids in the prevention of several chronic diseases is the subject of intense research, and soybean isoflavones have been the focus of particular attention (1-3). Assessment of the potential importance of flavonoids in human health, however, should be supported by the best knowledge of the absorption, distribution, metabolism, and excretion of these substances after ingestion.

Estrogen replacement therapy is effective in prevention as well as in the treatment and reversal of postmenopausal bone loss. However, this therapy is associated with serious side effects, such as breast or uterine cancer (4). Recent reports have concluded that the combined use of estrogen and progesterone as part of hormone replacement therapy is partially effective in the prevention of coronary heart disease and cognitive decline (5, 6). Consequently, there is considerable interest in the identification of alternative estrogens for the prevention of these chronic diseases. Soybean contains large quantities of isoflavones, the so-called phytoestrogens. These substances include genistein, daidzein, and glycitein, which have structural similarities to 17ß-estradiol and exhibit estrogenic-like effects by binding to estrogen receptors (5). Epidemiologic studies indicate a lower incidence of osteoporosis in populations who consume more soybean and soy product (7).

In postmenopausal women, soybean isoflavones are an alternative to conventional hormone replacement therapy because of their cholesterol-lowering action and hot flush prevention (8-10) and because of their effect on bone (11-13). Furthermore, daily consumption of soy food may induce endocrine effects in postmenopausal women (14, 15).

Bacterial intestinal glucosidases (ie, from lactobacilli, bacteroides, and bifidobacteria) have an important role in the absorption of isoflavones (16). Insoluble dietary fibers such as fructooligosaccharides and inulin may stimulate the growth of these bacteria in the colon (17). Thus, it is possible that supplementation with inulin may influence plasma concentrations of soybean isoflavones, possibly by increasing their absorption. Because of the relevance of isoflavones on alimentation after menopause, the present study investigated the influence of inulin on plasma concentrations of soybean isoflavones in healthy postmenopausal women.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Isoflavone formulations
We compared 2 drinkable formulations (prepared by Pharbenia-Bayer, Milan, Italy) containing 40 mg of a conjugated form of soybean isoflavones (25 mg free form): 6 mg daidzein, 18 mg genistein, and 1 mg glycitin. Both formulations also contained 500 mg Ca and 7.5 µg (equivalent to 300 units) vitamin D3. The formulations identified as Iso contained no inulin, whereas the Iso+Inu formulations also contained 3.66 g inulin.

Subjects
Twelve healthy postmenopausal women aged 51–64 y participated in this study. They were derived from a group of 32 volunteers initially prescreened and selected by phone interview from 76 volunteers who responded to an announcement posted in the local media. Screening of recruited volunteers concerned general health status, body mass index (BMI; in kg/m2), gastrointestinal function, and dietary habits (with the use of a dietary questionnaire). Volunteers were excluded if they had known or suspected hypersensitivity toward any of the constituents of the study medication or an allergy, had given blood within the past 3 mo, had any condition likely to change the absorption of the study medication, or had a BMI < 18 or > 30. The subjects were asked not to change their dietary habits, not to consume food containing soybean products or isoflavones, and not to change their physical activity patterns during the period of the study. In particular, they were instructed to consume no soy products from the time of screening until the end of the trial. The study was conducted at the University of Catania Medical Center (UCMC) in accordance with the protocol, good clinical practice requirements, and the principles of the Declaration of Helsinki and the applicable regulatory requirements. All subjects provided written informed consent. The study design and protocol, the informed consent text, and the fee amount for the subjects were approved by the Ethical Committee of the UCMC.

Experimental design
The crossover study was double-blind and randomized and consisted of 2 experimental phases. On day 1 of the first experimental phase, the subjects who had fasted overnight (14 h) were admitted to the UCMC. A venous blood sample (0 time) was collected into heparinized tubes. Within 30 min, the subjects consumed a standard breakfast and thereafter 1 of the 2 experimental formulations according to the randomization assignment for this phase. Breakfast consisted of milk and 6 biscuits and optional coffee or tea with sugar. Additional blood samples were withdrawn 1, 2, 3, 4, 6, 10, and 12 h after intake of the study formulation. The subjects remained at the UCMC during the 12-h period. They consumed a standard lunch at noon after blood was drawn at 4 h and consumed dinner at 2100 after blood was drawn at 12 h. Lunch consisted of lettuce, sliced tomato, shredded carrot, 2 pieces of white bread, tuna, mayonnaise, a fresh apple, a small package of butter cookies, and regular ginger ale. Italian dressing, salt, and pepper were optional. Dinner consisted of tomato soup, herbed chicken prepared with garlic powder, corn oil, oregano, cooking sherry, broccoli, a dinner roll, butter, sparkling water, and salt and pepper (optional). The subjects spent the night at the UCMC to provide a blood sample 24 h after intake of the study formulation. They then consumed the formulation twice daily, always at 0800 and 2000, and returned to the UCMC 20 d later. Blood samples were drawn according to the same procedure as described for day 1 of the first experimental phase. After a 7-d washout period, the subjects were readmitted to the UCMC, and the same procedure used during the first phase was repeated in the second experimental phase according to the randomization assignment applied for this phase. Blood samples (8 mL) were obtained by venipuncture via an indwelling catheter for the more frequent samplings or were collected into evacuated tubes for the later sample times, depending on the choice of the individual. Blood samples were centrifuged at 3000 x g for 10 min at 4 °C within 30 min of blood withdrawal. Plasma was separated and stored at –20 °C until analyzed.

Adverse events experienced throughout the study were recorded for each subject. The Common Toxicity Criteria suggested by the National Cancer Institute (Bethesda, MD) were used to assign a severity grade to each event.

Measurement of plasma isoflavones
Concentrations of isoflavones (daidzein and genistein) were measured in plasma samples by HPLC with electrochemical detection (HPLC/ECD). Estriol 3-(ß-glucuronide) was used as internal standard. Daidzein (product no. D7802), genistein (product no. G6776), and estriol 3-(ß-glucuronide) sodium salt (product no. E2002) were obtained from Sigma-Aldrich (St Louis, MO). Plasma preparations were derived according to a previously described HPLC-ECD procedure (18). One milliliter of plasma was mixed with 15 µL of 60 µg/mL estriol 3-(ß-glucuronide) solution, 0.25 mL of 1.0 mol ammonium acetate buffer/L (pH 5.0), and 1000 units ß-glucuronidase from Helix pomatia (Sigma, St Louis, MO) and incubated overnight at 37 °C to release the free forms of isoflavones from the glucuronide. After the addition of 0.1 mL glacial acetic acid, the hydrolysates were washed with 5.0 mL hexane.

Daidzein and genistein were extracted twice with 3 mL ethyl ether, and the extracts were evaporated with a vacuum system (Büchi multiple evaporator); the resulting residue was dissolved in 100 µL methanol followed by the addition of 100 µL mobile phase and an aliquot of 100 µL was injected into the HPLC column. The HPLC system was composed of a ProStar 410 AutoSampler VARIAN (Palo Alto, CA) series, ProStar 230 Solvent Delivery Module, and an 8-channel CoulArray detector ESA (Chelmsford, MA) model 5600A. Applied potentials were 460, 530, and 560 mV. The separation was done on a polar column (LiChrospher 60RP-select B, 125 mm x 4 mm, 5 µm; Merck, Darmstadt, Germany) and precolumn (LiChroCart, 4 mm x 4 mm, 5 µm; Merck, Darmstadt, Germany). The mobile phase was composed of 2 mixtures: mixture A consisted of water-methanol-acetonitrile (55:40:4, by vol) containing 0.2 mol ammonium acetate buffer/L (pH 4.8); mixture B consisted of water-methanol-acetonitrile (20:75:5, by vol) containing 0.2 mol ammonium acetate buffer/L (pH 4.8). The flow rate was set at 0.7 mL/min. A gradient in 10 min, from 0% (by vol) to 70% of mobile phase B, was introduced 10 min after injection. At 25 min, the system returned to 100% A in 5 min and was kept under this condition for 3 min to reequilibrate. The eluent of isoflavones was quantified by determining the peak areas in the chromatograms calibrated against known amounts of standards with high purity (>99%). All plasma samples collected from each subject during the 2 phases were analyzed in the same batch. The postprandial absorption and metabolism curves for genistein and daidzein were constructed by plotting plasma concentrations over time. The maximum concentration in plasma (Cmax) postprandially, the time for the maximum concentration to be reached (tmax), and the area under the curve (AUC0–24) were determined from the curves. Analyses were performed at the Pharmacokinetic Unit, Unifarm Research Center, University of Catania, Catania, Italy

Statistical analysis
The analysis of variance was performed after logarithmic transformation of AUC0–24 and Cmax values by evaluating the sequences, subjects, periods, and treatments. The SAS statistical software package was used to analyze the data. The area under the curve (AUC0–24) was calculated by using the Westlake (19) and Schuirmann (20) tests; tmax was determined with a nonparametric test (Wilcoxon's matched-pair ranks test). A P value <0.05 was considered to indicate a significant difference.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The postprandial plasma concentrations and time curves for daidzein and genistein in postmenopausal women after intake of the Iso and Iso+Inu formulations are depicted in Figure 1Go and Figure 2Go, and the pharmacokinetic parameters of these concentrations and time curves are summarized in Table 1Go and Table 2Go. Because there was considerable variation in the rate of absorption and appearance of isoflavones in plasma between the subjects, the AUC0–24 values for daidzein and genistein from the study formulations are shown in Tables 1Go and 2Go. Because all of the subjects consumed the same defined and controlled diet during the first 24 h on days 1 and 21 of each experimental phase while they stayed at the UCMC, we compared the AUC0–24 values for plasma daidzein and genistein.


Figure 1
View larger version (30K):
[in this window]
[in a new window]

  		FIGURE 1.. Mean plasma daidzein concentrations over a 24-h observation period in 21 healthy postmenopausal women. Each of the following 2 formulations was consumed twice daily for 21 d: a formulation containing soybean isoflavones without inulin (A) and a formulation containing soybean isoflavones with 3.66 g inulin (B). Basal values represent the concentration time curve on day 1; final values represent the concentration time curve on day 21.

 

Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		FIGURE 2.. Mean plasma genistein concentrations over a 24-h observation period in 12 healthy postmenopausal women. Each of the following 2 formulations was consumed twice daily for 21 d: a formulation containing soybean isoflavones without inulin (A) and a formulation containing soybean isoflavones with 3.66 g inulin (B). Basal values represent the concentration time curve on day 1; final values represent the concentration time curve on day 21.

 

View this table:
[in this window]
[in a new window]

  		TABLE 1. Pharmacokinetics parameters of daidzein1

 

View this table:
[in this window]
[in a new window]

  		TABLE 2. Pharmacokinetics parameters of genistein1

 
After 21 d of supplementation with soybean isoflavones, the AUC0–24 values for daidzein and genistein appeared to be higher than those at baseline (day 1) after the consumption of both the Iso and Iso+Inu formulations (Table 1Go and 2Go, respectively). However, the AUC0-24 values on day 21 for both isoflavones were higher after the Iso+Inu formulation than after the Iso formulation. This increase was 38% (95% CI: 5.6) for daidzein and 91% (95% CI: 12.2) for genistein.

Plasma Cmax values of daidzein appeared to be higher after 21 d of supplementation with both the Iso and Iso+Inu formulations (Table 1Go). In contrast, plasma Cmax values of genistein appeared to be higher only after supplementation with the Iso+Inu formulation.

As shown in Tables 1Go and 2Go, we observed a decrease in tmax values for daidzein and genistein after 21 d of supplementation with both the Iso and Iso+Inu formulations. However, the tmax value after supplementation with the Iso+Inu formulation was not significantly different from that after the Iso formulation on day 21 for either isoflavone. No adverse events were recorded for any of the subjects participating in the trial.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The aim of the present study was to investigate whether inulin enhances soybean isoflavone absorption in postmenopausal women. The results indicated a significant difference in plasma isoflavones concentrations as a result of the presence of inulin. In fact, daidzein and genistein absorption appeared to be relatively faster, and Cmax values for plasma isoflavones were found at times ranging from 2 to 8 h after ingestion. Furthermore, after a 21-d supplementation period, plasma concentrations of both daidzein and genistein were significantly higher in subjects who took isoflanoves with inulin. This difference was particularly evident for genistein, the AUC0–24 of which increased by {approx}91% in the subjects who consumed isoflavones with inulin for 21 d compared with the increase in the daidzein AUC0–24 of only {approx}38%.

Equol is one of the daidzein metabolites produced by the intestinal microflora and absorbed in plasma, where it remains for a relatively longer time than genistein and daidzein (21). Because equol concentrations were not measured in our samples, we do not know whether inulin in the Iso+Inu formulation caused modifications in plasma equol concentrations. However, it should be considered that other studies did not consider plasma equol concentrations as an important measure of soybean isoflavone pharmacokinetics (22).

It is not easy to explain the mechanism by which isoflavone absorption was facilitated by inulin intake under the present experimental conditions. The chemical forms in which isoflavones appear in food or supplements have been considered to be important to their plasma concentrations and, thus, for their biological activity. Isoflavones in soybean exist in 4 chemical forms: aglucone, glucoside, acetylglucoside, and malonylglucoside. However, the glucoside forms are predominant (23) and represent the major naturally occurring isoflavones in soybean and soybean-based food products (24, 25), although variation in food-processing techniques may alter the relative content of acylglucoside, malonylglucoside, and simple glucosides (26). After ingestion, isoflavone glucosides are hydrolyzed to their aglucones by phlorizin lactose hydrolase in the apical membrane of the lumen of the small intestine and by bacterial intestinal glucosidases (ie, from lactobacilli, bacteroides, and bifidobacteria) (16, 27). Conversion of daidzein into its metabolites dihydrodaidzein, O-desmethylangolesin, and equol also precedes absorption from the colon. After hepatic uptake and excretion into the bile of the ß-glycuronides genistein, glycitein, and daidzein and its metabolites, a second round of hydrolysis occurs (28). Insoluble dietary fibers, such as fructooligosaccharides and inulin, may stimulate the growth of these bacteria in the colon (17). Thus, it is possible that inulin-stimulated bacterial growth induced soybean glucoside conversion and, hence, facilitated their absorption.

It is possible that inulin altered the pharmaceutical properties of the formulations that were prepared for this study. This is a well-known problem in the pharmaceutical industry dealing with food products, which puts considerable effort into the preparation of drugs to overcome this difficulty. Concern for this issue comes from the study by Busby et al (21), which suggests that significant amounts of isoflavones are never absorbed or excreted in the feces or may be metabolized to other compounds that were not measured.

The intestinal absorption of isoflavones requires a release of free forms from glucosidic conjugates. Thus, intestinal absorption of glucoside forms of isoflavones can slow down until they enter the large intestine, where colonic microflora may release aglucones (29). However, glucoside forms are subjected to hydrolysis by ß-glycosidases in the small intestine and appear in plasma within a short period of time (30, 31). Other factors, including dietary habits, the food matrix, the extent of intestinal bacterial fermentation, intestinal transit time, and age may influence the intestinal metabolism and plasma concentrations of isoflavones in humans (32, 33).

Whether a 7-d washout period was sufficient to avoid the possible enterohepatic recirculation of isoflavones is not certain. In fact, it is possible that a pool of isoflavones in the gut undergoes enterohepatic recirculation, which allows a postprandial reentry into the blood and alters the AUC calculations for the new preparation. However, preclinical studies in rats suggest that genistein is absorbed very well from the intestines and is excreted into the bile in only small proportions. An important factor that may alter the initial intestinal absorption and the subsequent enterohepatic recirculation of genistein is bacterial metabolism (34). Furthermore, pharmacokinetic analysis of the plasma curves in the present study showed the mean (±SD) elimination half-life to be 9.34 ± 1.3 h for daidzein and 6.78 ± 0.84 h for genistein. For this reason, a 7-d washout was sufficient to avoid any possible enterohepatic recirculation of isoflavones, as also indicated by other studies (35).

In the present study, all subjects were selected from a pool of postmenopausal women after they were screened for general health status, BMI, gastrointestinal function, and dietary habits. It is important to note that, at least for the 24-h period on day 1 and day 21 of each phase at the UCMC, all of the subjects consumed the defined diet at breakfast, lunch, and dinner. Thus, the food matrix, which may influence plasma concentrations of isoflavones during the absorption period (32), was the same for all of the participants and thus we concluded that the appearance of daidzein and genistein in plasma was not influenced by food.

The influence of menopause on the isoflavone pharmacokinetic parameters studied herein warrants discussion. No women who still had menstrual cycles were admitted as controls for the postmenopausal subjects. Thus, no information exists on the possible influence of menopause on plasma isoflavone concentrations. However, it should be noted that the pharmacokinetic parameters measured in the postmenopausal women in the present study were lower than those described by others in premenopausal subjects (17, 19). Thus, it seems likely that postmenopausal women may show decreased absorption of isoflavones and need higher doses to achieve plasma concentrations similar to those of younger subjects. Indeed, gut microflora is important for plasma soybean isoflavone concentrations in women (19). Menopausal subjects are primarily interested in isoflavone supplementation because these substances are chemically and functionally similar to 17ß-estradiol and seem to be effective during menopause at preventing osteoporosis (7, 11-13), lowering plasma cholesterol concentrations, and preventing hot flushes (8-10) as an alternative to conventional hormone replacement therapy. A daily intake of {approx}50 mg isoflavones, which is equal to the dose adopted in the present study (6 mg daidzein, 18 mg genistein, and 1 mg glycitin twice daily), seems to have been based largely on the early observation that the daily consumption of soy foods providing 45 mg isoflavones resulted in hormonal changes in menopausal women (14, 15).

The excellent tolerability of soybean preparations used in the present trial does not deserve comment. Indeed, in another study, dietary supplementation with purified unconjugated isoflavones administered in single doses greatly exceeding normal dietary intakes resulted in minimal clinical toxicity (22).

More research is required to establish precisely the health benefits of soybean isoflavones, the site and the mechanism of their absorption, and their interaction with inulin. Interestingly, a randomized, double-blind, placebo-controlled study recently found that dietary supplementation of functional foods with isoflavones may cause changes in the diversity and composition of dominant intestinal bacterial communities in postmenopausal women (36). Another unanswered question refers to the effects of total isoflavones compared with those of their individual metabolites on calcium absorption and bone health. However, the present study clearly showed that supplementation with inulin increases plasma concentrations of soybean isoflavones and suggests that this substance should be consumed with isoflavones by subjects who may need isoflavone supplementation.


   ACKNOWLEDGMENTS
 
The authors' responsibilities were as follows—CP, BM, and GML: analytic measurements; MGP: quality insurance; TI, MRM, and MAR: clinical portion of the study; and FD: study coordinator. No conflicts of interest were disclosed by any of the authors.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113–31.[Medline]
  2. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996;87:897–904.[Medline]
  3. Hertog MGL, Feskens EJ, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 1993;342:1007–11.[Medline]
  4. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA 2002;288:321–33.[Abstract/Free Full Text]
  5. Setchell KDR, Adlercreutz H. Mammalian lignans and phytoestrogens. Recent studies on their formation, metabolism and biological role in health and disease. New York, NY: Academic Press, 1988:315–45.
  6. Dodge JA, Glasebrook AL, Magee DE, et al. Environmental estrogens; effect on cholesterol lowering and bone in the ovariectomized rat. J Steroid Biochem Mol Biol 1996;59:155–61.[Medline]
  7. Adlercreutz H, Mazur W. Phytoestrogens and western diseases. Ann Med 1997;29:95–120.[Medline]
  8. Crouse JR, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amount of isoflavones on plasma concentrations of lipid and lipoproteins. Arch Intern Med 1999;159:2070–6.[Abstract/Free Full Text]
  9. Brzezinski A, Adlercreutz H, Shaoul REA. Short-term effect of phytoestrogen-rich diet on menopausal women. Menopause 1997;4:89–94.
  10. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary supplementation on hot flushes. Obstet Gynecol 1998;91:6–11.[Medline]
  11. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in menopausal women. Am J Clin Nutr 1998;68(suppl):1375S–9S.[Abstract]
  12. Alekel L, St Germain A, Peterson C, Hanson K, Steward J, Toda T. Isoflavone-rich soy protein isolate bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;844–52.
  13. Lydeking-Olsen E, Jensen JBE, Setchell KDR, Damhus M, Jensen TH. Isoflavone-rich soymilk prevents bone loss in the lumbar spine of menopausal women. A 2 year study. J Nutr 2002;132(suppl):581S.
  14. Cassidy A, Bingham S, Setchell KDR. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 1994;60:333–40.[Abstract/Free Full Text]
  15. Cassidy A, Bingham S, Setchell KDR. Biological effects of isoflavones in young women: importance of the chemical composition of soybean products. Br J Nutr 1995;74:587–601.[Medline]
  16. Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S. Bioavailability of soybean isoflavones depends on gut microflora in women. J Nutr 1995;125:2307–15.[Abstract/Free Full Text]
  17. McFarlane GT, Cumming JH. The colonic flora, fermentation, and large bowel digestive function. New York, NY: Raven Press, 1991:51–93.
  18. Coward L, Kirk M, Albin L, Barnes S. Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry. Clin Chim Acta 1996;247:121–42.[Medline]
  19. Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972;61:1340–51.[Medline]
  20. Schuirmann DJ. Design of bioavailability/bioequivalence studies. Drugs Inform J 1990;24:315–8.
  21. Busby MG, Jeffcoat AR, Bloedon LT, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002;75:126–36.[Abstract/Free Full Text]
  22. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072–9.[Abstract/Free Full Text]
  23. US Department of Agriculture. Database on the isoflavone content of foods. 1999. Internet: http://www.nal.usda.gov/fnic/foodcomp/Data/isofl/isoflav.html (accessed 28 February 2003).
  24. Wang HJ, Murphy PA. Isoflavone content in commercial soybean foods. J Agric Food Chem 1994;42:1666–73.
  25. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein and daidzein, and their ß-glucosides conjugates: anti-tumor isoflavones in soy bean foods from American and Asian diets. J Agric Food Chem 1993;41:1961–7.
  26. Xu X, Wang HJ, Murphy PA, Hendrich S. Neither background diet nor type of soy food affects short-term isoflavone bioavailability in women. J Nutr 2000;130:798–801.[Abstract/Free Full Text]
  27. Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Nutr 1984;40:569–78.[Abstract/Free Full Text]
  28. Sfakianos J, Coward L, Kirk M, Barnes S. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J Nutr 1997;127:1260–8.[Abstract/Free Full Text]
  29. Kuhnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 1976;24:117–91.[Medline]
  30. Day AJ, DuPont MS, Ridley S, et al. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver betaglucosidase activity. FEBS Lett 1998;436:71–5.[Medline]
  31. King RA, Bursill DB. Plasma and urinary kinetics of isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998;67:867–72.[Abstract]
  32. Setchell KD. Phytoestrogens: the biochemistry, physiology and implications for human health of soy isoflavones. Am J Clin Nutr 1998;68(suppl):1333S–46S.[Abstract]
  33. Aldercreutz H, Fotsis T, Lampe J, et al. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Invest Suppl 1993;215:5–18.
  34. Blaut M, Schoefer L, Braune A. Transformation of flavonoids by intestinal microorganism. Int J Vitam Nutr Res 2003;73:79–87.[Medline]
  35. Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 2002;76:588–94.[Abstract/Free Full Text]
  36. Clavel T, Fallani M, Lepage P, et al. Isoflavones and functional foods alter the dominant intestinal microbiota in postmenopausal women. J Nutr 2005;135:2786–92.[Abstract/Free Full Text]
Received for publication June 2, 2006. Accepted for publication April 11, 2007.




This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
K. D. Setchell, X. Zhao, P. Jha, J. E Heubi, and N. M Brown
The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers
Am. J. Clinical Nutrition, October 1, 2009; 90(4): 1029 - 1037.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.
Agricola
Right arrow Articles by Piazza, C.
Right arrow Articles by Drago, F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS